LBF20207PG26: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
|LipidBank=XPR1511 | |LipidBank=XPR1511 | ||
|LipidMaps=LMFA03010026 | |LipidMaps=LMFA03010026 | ||
|SysName=7- [ | |SysName=7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-trans-1-octenyl)- cyclopentan-1R -yl] -cis-5-heptenoic acid | ||
|Common Name=&&15-keto Prostaglandin F_2 alpha&&7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-1(E)-octenyl)- cyclopentan-1R -yl ] -5-(Z)-heptenoic acid&& | |Common Name=&&15-keto Prostaglandin F_2 alpha&&7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-1(E)-octenyl)- cyclopentan-1R -yl ] -5-(Z)-heptenoic acid&& | ||
|Source=15-Keto-prostaglandin F2 alpha is the oxidized product of prostaglandin F2 alpha by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group [[Reference:Hansen_HS:,Prostaglandins,1976,12,647|{{RelationTable/GetFirstAuthor|Reference:Hansen_HS:,Prostaglandins,1976,12,647}}]]. | |Source=15-Keto-prostaglandin F2 alpha is the oxidized product of prostaglandin F2 alpha by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group [[Reference:Hansen_HS:,Prostaglandins,1976,12,647|{{RelationTable/GetFirstAuthor|Reference:Hansen_HS:,Prostaglandins,1976,12,647}}]]. |
Latest revision as of 08:30, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1511 |
LipidMaps | LMFA03010026 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207PG26 |
15-keto Prostaglandin F2α | |
---|---|
Structural Information | |
7- [ (3R,5S) -Dihydroxy-2R - (3-oxo-trans-1-octenyl)- cyclopentan-1R -yl] -cis-5-heptenoic acid | |
| |
15-KETO-PGF2α | |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CCC(=O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC |
Physicochemical Information | |
15-Keto-prostaglandin F2 alpha is the oxidized product of prostaglandin F2 alpha by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group Hansen_HS . | |
15-Keto-prostaglandin F2 alpha is further metabolized by its Delta 13-reduction, beta -oxidation and omega oxidation. The ultimate metabolite is 5 alpha ,7 alpha -dihydroxy-11-keto-tetranorprosta-1,16-dioic acid, and excreted in urine Granstrom_E et al.. | |
It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase Anggard_E . | |
cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned Ensor_CM et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|